Graves’ Disease – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
Graves' Disease is an autoimmune disorder that results in hyperthyroidism or an overactive thyroid. With this disease, the immune system attacks the thyroid and causes it to make more thyroid hormone than the body needs. The thyroid is a small, butterfly-shaped gland in the neck. Thyroid hormones control how the body uses energy, so they affect nearly every organ in your body, even the way your heartbeats. If left untreated, hyperthyroidism can cause serious heart, bones, muscles, menstrual cycle, and fertility problems. Untreated hyperthyroidism can cause complications for the mother and the baby during pregnancy. Graves' Disease can also have an impact on the eyes and skin. People who have other autoimmune disorders are more likely to develop Graves' Disease than those who do not. Rheumatoid arthritis, a condition that affects the joints and sometimes other body systems; pernicious anemia, an infection caused by a vitamin B12 deficiency; lupus, a chronic or long-term a disorder that can affect many parts of the body; and Addison's Disease, a hormonal disorder, are all conditions associated with Graves' Disease. Celiac disease is a digestive disorder, Vitiligo is a condition in which some areas of the skin are not pigmented, and type 1 diabetes is all possible.
The incidence population ranges from 45
to 53 cases per 100,000 population in the USA.
The competitive
landscape of Graves’ Disease includes country-specific approved and pipeline
therapies. Any asset/product-specific designation or review and Accelerated
Approval are tracked and supplemented with analyst commentary.
KOLs insights on Graves’
Disease across the 8 MM market from the center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Graves’
Disease Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 WP1302 Worg
Pharmaceuticals (Hangzhou) Co., Ltd. Phase
1
2 Secukinumab Novartis
Pharmaceuticals Phase 3
3 K1-70 AV7 Limited Phase 1
4 Teprotumumab Horizon
Pharma USA, Inc. Phase 3
5 VRDN-001 Viridian
Therapeutics, Inc. Phase 2
6 Linsitinib VasaraGen,
Inc. Phase 3
Comments
Post a Comment